Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

0.2979 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bluebird Bio

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
Bluebird Bio's Q3 earnings report showed a narrower-than-expected EPS loss but missed sales targets, leading to a JP Morgan downgrade and cash concerns. 
Via Benzinga
Exploring bluebird bio's Earnings Expectations
Via Benzinga
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
A recent report reveals an increase in cancer cases among children treated with Bluebird Bio's Skysona gene therapy, raising concerns about the therapy's safety. Seven children in clinical trials have... 
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
The Analyst Verdict: bluebird bio In The Eyes Of 5 Experts
Via Benzinga
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year
Bluebird bio announces restructuring plans to reduce costs by 20% and achieve cash flow break-even by late 2025. The initiative includes a 25% workforce reduction and focuses on advancing key gene... 
Via Benzinga
What 4 Analyst Ratings Have To Say About bluebird bio
Via Benzinga
Is Bluebird Bio Stock a Buy?
It won't be easy for the company to bounce back. 
Via The Motley Fool
Is Bluebird Bio Stock a Buy?
This small biotech is struggling to fly -- and investors should probably steer clear. 
Via The Motley Fool
Earnings Scheduled For November 14, 2024
Via Benzinga
This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Better Buy: Bluebird Bio Vs. Novavax
Who wins this face-to-face between two beaten-down biotechs? 
Via The Motley Fool
Is This Beaten-Down Stock a Good Acquisition Target?
This company has proven its innovative abilities, but that's not enough to outperform the market. 
Via The Motley Fool
Peeling Back The Layers: Exploring bluebird bio Through Analyst Insights
Via Benzinga
Peering Into bluebird bio's Recent Short Interest
Via Benzinga
Is Bluebird Bio Stock a Buy Now?
Are you feeling brave? 
Via The Motley Fool
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain. 
Via The Motley Fool
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Bluebird Bio Stock Flew Higher Than the Market Today
The company was thrown a financial lifeline. 
Via The Motley Fool
Why Bluebird Bio Stock Dived Into the Red on Tuesday
The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation. 
Via The Motley Fool
Forecasting The Future: 6 Analyst Projections For bluebird bio
Via Benzinga
(BLUE) - Analyzing bluebird bio's Short Interest
Via Benzinga
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today
The answer hardly inspires confidence. 
Via The Motley Fool
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.